{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:43:16Z","timestamp":1771555396139,"version":"3.50.1"},"reference-count":111,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.semerg.2023.102136","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T04:13:51Z","timestamp":1701749631000},"page":"102136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Situaci\u00f3n actual de los anticoagulantes orales de acci\u00f3n directa en atenci\u00f3n primaria de Espa\u00f1a. Posicionamiento de SEMERGEN en 2023"],"prefix":"10.1016","volume":"50","author":[{"given":"J.","family":"Polo-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Pallares-Carratal\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Turegano-Yedro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Romero-Vigara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Prieto-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cinza-Sanjurjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2023.102136_bib0560","unstructured":"Llisterri JL, Pallar\u00e9s V, Polo J, Prieto MA. Posicionamiento de SEMERGEN sobre la utilizaci\u00f3n de los anticoagulantes oralesde acci\u00f3n directa. Madrid. 2017. Disponible en: https:\/\/semergen.es\/resources\/files\/biblioteca\/guiaClinicas\/Posicionamiento%20ACODs%20SEMERGEN.pdf"},{"key":"10.1016\/j.semerg.2023.102136_bib0565","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.semerg.2019.06.002","article-title":"Utilizaci\u00f3n de los anticoagulantes orales de acci\u00f3n directa en Atenci\u00f3n Primaria de Espa\u00f1a. Posicionamiento de SEMERGEN ante la situaci\u00f3n actual","volume":"45","author":"Llisterri Caro","year":"2019","journal-title":"Semergen."},{"key":"10.1016\/j.semerg.2023.102136_bib0570","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J."},{"key":"10.1016\/j.semerg.2023.102136_bib0575","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.semerg.2023.102136_bib0580","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitaminK antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace."},{"key":"10.1016\/j.semerg.2023.102136_bib0585","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.semerg.2023.102136_bib0590","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.recesp.2011.08.008","article-title":"Pacientes con fibrilaci\u00f3n auricular asistidos en consultas de atenci\u00f3n primaria. EstudioVal-FAAP","volume":"65","author":"Barrios","year":"2012","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0595","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.recesp.2013.07.015","article-title":"Prevalencia de fibrilaci\u00f3n auricular en Espa\u00f1a. Resultados del estudio OFRECE","volume":"67","author":"G\u00f3mez-Doblas","year":"2014","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0600","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1747493019897870","article-title":"Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge","volume":"16","author":"Lippi","year":"2021","journal-title":"Int J Stroke."},{"key":"10.1016\/j.semerg.2023.102136_bib0605","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart Disease and Stroke Statistics \u2014 2023 update: A report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation."},{"key":"10.1016\/j.semerg.2023.102136_bib0610","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12955-023-02112-2","article-title":"The prognostic value of quality of life in atrial fibrillation on patient value","volume":"21","author":"Theunissen","year":"2023","journal-title":"Health Qual Life Outcomes."},{"key":"10.1016\/j.semerg.2023.102136_bib0615","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ahj.2014.02.003","article-title":"Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"167","author":"Steinberg","year":"2014","journal-title":"Am Heart J."},{"key":"10.1016\/j.semerg.2023.102136_bib0620","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.tcm.2020.10.010","article-title":"Mortality in atrial fibrillation. Is it changing?","volume":"31","author":"Alonso","year":"2021","journal-title":"Trends Cardiovasc Med."},{"key":"10.1016\/j.semerg.2023.102136_bib0625","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.14-2414","article-title":"Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: Relation to atherosclerotic risk factors","volume":"147","author":"Pastori","year":"2015","journal-title":"Chest."},{"key":"10.1016\/j.semerg.2023.102136_bib0630","first-page":"9","article-title":"Prevenci\u00f3n del ictus en pacientes con fibrilaci\u00f3n auricular. Mejorar la protecci\u00f3n en la era de la COVID-19","volume":"21A","author":"Masjuan-Vallejo","year":"2021","journal-title":"Rev Esp Cardiol Supl."},{"key":"10.1016\/j.semerg.2023.102136_bib0635","doi-asserted-by":"crossref","first-page":"25","DOI":"10.33588\/rn.5901.2014037","article-title":"Manejo actual del tratamiento antitromb\u00f3tico en pacientes con fibrilaci\u00f3n auricular no valvular y antecedentes de ictus o ataque isqu\u00e9mico transitorio","volume":"59","author":"Masju\u00e1n","year":"2014","journal-title":"Rev Neurol."},{"key":"10.1016\/j.semerg.2023.102136_bib0640","first-page":"1321","article-title":"Health care resource utilization and costs associated with atrial fibrillation and rural-urban disparities","volume":"28","author":"Jiang","year":"2022","journal-title":"J Manag Care Spec Pharm."},{"key":"10.1016\/j.semerg.2023.102136_bib0645","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/14737167.2022.2045955","article-title":"Healthcare resource utilization in patients with newly diagnosed atrial fibrillation in the United States","volume":"22","author":"Zeitler","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"10.1016\/j.semerg.2023.102136_bib0650","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: An integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat Rev Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0655","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1055\/a-1515-9630","article-title":"Adherence to the \u2018atrial fibrillation better care\u2019 (ABC) pathway in patients with atrial fibrillation","volume":"122","author":"Romiti","year":"2022","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.semerg.2023.102136_bib0660","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.recesp.2021.07.012","article-title":"Epidemiolog\u00eda del ictus cardioemb\u00f3lico y su asociaci\u00f3n con la penetraci\u00f3n de los ACOD en Espa\u00f1a: primer estudio poblacional 2005-2018","volume":"75","author":"D\u00edaz-Guzm\u00e1n","year":"2022","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0665","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.gheart.2017.01.015","article-title":"The World Heart Federation roadmap for nonvalvular atrial fibrillation","volume":"12","author":"Murphy","year":"2017","journal-title":"Glob Heart."},{"key":"10.1016\/j.semerg.2023.102136_bib0670","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1253\/circj.CJ-12-1036","article-title":"Stroke and thromboembolism in atrial fibrillation","volume":"76","author":"Pisters","year":"2012","journal-title":"Circ J."},{"key":"10.1016\/j.semerg.2023.102136_bib0675","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.amjcard.2015.08.049","article-title":"Stroke risk factors beyond the CHA(2)DS(2)-VASc score: can we improve our identification of \u2018high stroke risk\u2019 patients with atrial fibrillation?","volume":"116","author":"Szymanski","year":"2015","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0680","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/archinte.158.12.1316","article-title":"Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials","volume":"158","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semerg.2023.102136_bib0685","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1055\/s-0039-1696955","article-title":"The use of biomarkers in clinical management guidelines: A critical appraisal","volume":"119","author":"Esteve-Pastor","year":"2019","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.semerg.2023.102136_bib0690","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest."},{"key":"10.1016\/j.semerg.2023.102136_bib0695","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest."},{"key":"10.1016\/j.semerg.2023.102136_bib0700","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J."},{"key":"10.1016\/j.semerg.2023.102136_bib0705","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0710","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182\u00a0678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J."},{"key":"10.1016\/j.semerg.2023.102136_bib0715","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: A derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.semerg.2023.102136_bib0720","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2012.06.019","article-title":"Performance of the HEMORR2HAGES, ATRIA and HAS-BLED bleeding risk prediction scores in anticoagulated patients with atrial fibrillation: The AMADEUS study","volume":"60","author":"Apostolakis","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0725","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/europace\/euaa324","article-title":"Changing paradigms: From prevention of thromboembolic events to improved survival in patients with atrial fibrillation","volume":"23","author":"Escobar","year":"2021","journal-title":"Europace."},{"key":"10.1016\/j.semerg.2023.102136_bib0730","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.semerg.2023.102136_bib0735","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med."},{"issue":"6 Suppl","key":"10.1016\/j.semerg.2023.102136_bib0740","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitaminK antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest."},{"key":"10.1016\/j.semerg.2023.102136_bib0745","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10840-008-9210-9","article-title":"Advancement in antithrombotics for stroke prevention in atrial fibrillation","volume":"22","author":"Umer Usman","year":"2008","journal-title":"J Interv Card Electrophysiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0750","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccl.2007.12.005","article-title":"New anticoagulant agents: Direct thrombin inhibitors","volume":"26","author":"Nutescu","year":"2008","journal-title":"Cardiol Clin."},{"key":"10.1016\/j.semerg.2023.102136_bib0755","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2217\/cer.15.44","article-title":"Atrial fibrillation and chronic kidney disease: Focus on rivaroxaban","volume":"4","author":"Barrios","year":"2015","journal-title":"J Comp Eff Res."},{"key":"10.1016\/j.semerg.2023.102136_bib0760","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.recesp.2015.04.017","article-title":"Control de la anticoagulaci\u00f3n en pacientes con fibrilaci\u00f3n auricular no valvular asistidos en atenci\u00f3n primaria en Espa\u00f1a. Estudio PAULA","volume":"68","author":"Barrios","year":"2015","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0765","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.recesp.2014.04.020","article-title":"Evaluaci\u00f3n del grado de anticoagulaci\u00f3n de pacientes con fibrilaci\u00f3n auricular en el \u00e1mbito de atenci\u00f3n primaria de Galicia. Estudio ANFAGAL","volume":"68","author":"Cinza-Sanjurjo","year":"2015","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"key":"10.1016\/j.semerg.2023.102136_bib0770","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.medcli.2014.09.023","article-title":"Grado de control del tratamiento anticoagulante oral en los centros de Atenci\u00f3n Primaria de la Comunidad de Madrid: Estudio CHRONOS-TAO","volume":"145","author":"Alonso Roca","year":"2015","journal-title":"Med Clin."},{"key":"10.1016\/j.semerg.2023.102136_bib0775","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.recesp.2014.11.022","article-title":"Calidad de la anticoagulaci\u00f3n con antagonistas de la vitaminaK en Espa\u00f1a: prevalencia del mal control y factores asociados","volume":"68","author":"Anguita","year":"2015","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0780","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/clc.22397","article-title":"Quality of anticoagulation with vitaminK antagonists","volume":"38","author":"Bertomeu-Gonzalez","year":"2015","journal-title":"Clin Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0785","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.rce.2018.04.020","article-title":"Factores asociados al mal control de la anticoagulaci\u00f3n con antivitaminaK en pacientes con fibrilaci\u00f3n auricular no valvular atendidos en consultas de Medicina Interna y Neurolog\u00eda. Estudio ALADIN","volume":"218","author":"Contreras Muruaga","year":"2018","journal-title":"Rev Clin Esp (Barc)."},{"key":"10.1016\/j.semerg.2023.102136_bib0790","doi-asserted-by":"crossref","first-page":"e0164076","DOI":"10.1371\/journal.pone.0164076","article-title":"Quality of vitaminK antagonist control and 1-year outcomes in patients with atrial fibrillation: A global perspective from the GARFIELD-AF Registry","volume":"11","author":"Haas","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.semerg.2023.102136_bib0795","unstructured":"Garc\u00eda EI, Santi\u00f1\u00e1 M, Mira JJ, Carrillo Murcia I, Martin Delgado J. Atlas del mal control de la anticoagulaci\u00f3n con antivitaminaK en pacientes con fibrilaci\u00f3n auricular no valvular en Espa\u00f1a. Sociedad Espa\u00f1ola de Calidad Asistencial. Septiembre 2021. Disponible en: https:\/\/secardiologia.es\/images\/secciones\/clinica\/atlas-mal-control-anticoagulacion.pdf"},{"key":"10.1016\/j.semerg.2023.102136_bib0800","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.recesp.2020.06.009","article-title":"Carga y coste del mal control de la anticoagulaci\u00f3n con antagonistas de la vitaminaK en pacientes con fibrilaci\u00f3n auricular no valvular en Espa\u00f1a","volume":"74","author":"Barrios","year":"2021","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0805","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.recesp.2013.07.010","article-title":"Uso del tratamiento antitromb\u00f3tico seg\u00fan la escala CHA2DS2-VASc en los pacientes con fibrilaci\u00f3n auricular en atenci\u00f3n primaria","volume":"67","author":"Barrios","year":"2014","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0810","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamacardio.2015.0374","article-title":"Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: Insights from the NCDR PINNACLE Registry","volume":"1","author":"Hsu","year":"2016","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0815","doi-asserted-by":"crossref","first-page":"e0191592","DOI":"10.1371\/journal.pone.0191592","article-title":"Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation","volume":"13","author":"Bassand","year":"2018","journal-title":"PLoS One."},{"key":"10.1016\/j.semerg.2023.102136_bib0820","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.amjmed.2018.03.024","article-title":"Gender differences in antithrombotic treatment for newly diagnosed atrial fibrillation: The GLORIA-AF Registry Program","volume":"131","author":"Mazurek","year":"2018","journal-title":"Am J Med."},{"key":"10.1016\/j.semerg.2023.102136_bib0825","doi-asserted-by":"crossref","first-page":"e002275","DOI":"10.1136\/openhrt-2023-002275","article-title":"Determinants and clinical outcomes of patients who refused anticoagulation: Findings from the global GARFIELD-AF registry","volume":"10","author":"Apenteng","year":"2023","journal-title":"Open Heart."},{"key":"10.1016\/j.semerg.2023.102136_bib0830","unstructured":"Ficha t\u00e9cnica dabigatr\u00e1n [consultado 5 Sep 2023]. Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pradaxa-epar-product-information_es.pdf"},{"key":"10.1016\/j.semerg.2023.102136_bib0835","unstructured":"Ficha t\u00e9cnica rivaroxab\u00e1n [consultado 5 Sep 2023]. Disponible en: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2011\/20111209112692\/anx_112692_es.pdf"},{"key":"10.1016\/j.semerg.2023.102136_bib0840","unstructured":"Ficha t\u00e9cnica apixab\u00e1n [consultado 5 Sep 2023]. Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eliquis-epar-product-information_es.pdf"},{"key":"10.1016\/j.semerg.2023.102136_bib0845","unstructured":"Ficha t\u00e9cnica edoxab\u00e1n [consultado 5 Sep 2023]. Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lixiana-epar-product-information_es.pdf"},{"key":"10.1016\/j.semerg.2023.102136_bib0850","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2023.102136_bib0855","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2023.102136_bib0860","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2023.102136_bib0865","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2023.102136_bib0870","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet."},{"key":"10.1016\/j.semerg.2023.102136_bib0875","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.semerg.2016.01.016","article-title":"De los ensayos cl\u00ednicos a la pr\u00e1ctica cl\u00ednica. Evidencias con rivaroxab\u00e1n en el tratamiento anticoagulante del paciente con fibrilaci\u00f3n auricular no valvular","volume":"43","author":"Barrios","year":"2017","journal-title":"Semergen."},{"key":"10.1016\/j.semerg.2023.102136_bib0880","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ahj.2019.08.012","article-title":"Safety and effectiveness of dabigatran at 2years: Final outcomes from phaseII of the GLORIA-AF registry program","volume":"218","author":"Mazurek","year":"2019","journal-title":"Am Heart J."},{"key":"10.1016\/j.semerg.2023.102136_bib0885","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s40261-021-01091-w","article-title":"Effectiveness and safety of dabigatran compared to vitaminK antagonists in non-Asian patients with atrial fibrillation: A systematic review and meta-analysis","volume":"41","author":"Escobar","year":"2021","journal-title":"Clin Drug Investig."},{"key":"10.1016\/j.semerg.2023.102136_bib0890","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"Camm","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.semerg.2023.102136_bib0895","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH17-01-0068","article-title":"Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in \u2018real-world\u2019 clinical practice. A propensity-matched analysis of 76,940 patients","volume":"117","author":"Li","year":"2017","journal-title":"Thromb Haemost."},{"issue":"FI1","key":"10.1016\/j.semerg.2023.102136_bib0900","doi-asserted-by":"crossref","first-page":"f30","DOI":"10.1093\/ehjcvp\/pvaa079","article-title":"Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study","volume":"7","author":"De Groot","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"10.1016\/j.semerg.2023.102136_bib0905","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.rce.2023.03.007","article-title":"Patrones y resultados del cambio de anticoagulantes orales directos en la fibrilaci\u00f3n auricular no valvular: experiencia en la pr\u00e1ctica cl\u00ednica en Espa\u00f1a","volume":"223","author":"Rodilla","year":"2023","journal-title":"Rev Clin Esp (Barc)."},{"key":"10.1016\/j.semerg.2023.102136_bib0910","doi-asserted-by":"crossref","first-page":"e0279297","DOI":"10.1371\/journal.pone.0279297","article-title":"Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: Critical appraisal of real-world data","volume":"18","author":"Moret","year":"2023","journal-title":"PLoS One."},{"key":"10.1016\/j.semerg.2023.102136_bib0915","doi-asserted-by":"crossref","first-page":"1110036","DOI":"10.3389\/fphar.2023.1110036","article-title":"Sex and gender differences in the use of oral anticoagulants for non-valvular atrial fibrillation: A population-based cohort study in primary health care in Catalonia","volume":"14","author":"Giner-Soriano","year":"2023","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.semerg.2023.102136_bib0920","doi-asserted-by":"crossref","first-page":"601","DOI":"10.5603\/CJ.a2022.0044","article-title":"Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study","volume":"29","author":"Sanmart\u00edn Fern\u00e1ndez","year":"2022","journal-title":"Cardiol J."},{"key":"10.1016\/j.semerg.2023.102136_bib0925","first-page":"100913","article-title":"Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity","volume":"37","author":"Navarro-Almenzar","year":"2021","journal-title":"Int J Cardiol Heart Vasc."},{"key":"10.1016\/j.semerg.2023.102136_bib0930","doi-asserted-by":"crossref","first-page":"10993","DOI":"10.3390\/ijerph182010993","article-title":"Gender and socioeconomic inequality in the prescription of direct oral anticoagulants in patients with non-valvular atrial fibrillation in primary care in Catalonia (Fantas-TIC Study)","volume":"18","author":"Dalmau Llorca","year":"2021","journal-title":"Int J Environ Res Public Health."},{"key":"10.1016\/j.semerg.2023.102136_bib0935","first-page":"1210","article-title":"Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation","volume":"27","author":"Charlton","year":"2021","journal-title":"J Manag Care Spec Pharm."},{"key":"10.1016\/j.semerg.2023.102136_bib0940","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijcard.2021.05.036","article-title":"Antithrombotic strategies in elderly patients with atrial fibrillation revascularized with drug-eluting stents: PACO-PCI (EPIC-15) registry","volume":"338","author":"De la Torre Hernandez","year":"2021","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0945","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/16078454.2021.1892329","article-title":"Quality of life in patients with nonvalvular atrial fibrillation treated with oral anticoagulants","volume":"26","author":"Gabilondo","year":"2021","journal-title":"Hematology."},{"key":"10.1016\/j.semerg.2023.102136_bib0950","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijcard.2020.11.023","article-title":"Incidence, predictors of bleeding and prognosis of bleeding in anticoagulated nonagenarian patients with atrial fibrillation","volume":"327","author":"Dom\u00ednguez-Erquicia","year":"2021","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0955","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.aprim.2020.05.016","article-title":"Uso y adherencia a los anticoagulantes orales en Atenci\u00f3n Primaria en Catalu\u00f1a, Espa\u00f1a: estudio de cohortes con datos procedentes de registros electr\u00f3nicos de salud","volume":"52","author":"Giner-Soriano","year":"2020","journal-title":"Aten Primaria."},{"key":"10.1016\/j.semerg.2023.102136_bib0960","doi-asserted-by":"crossref","first-page":"116685","DOI":"10.1016\/j.jns.2020.116685","article-title":"Influence of oral anticoagulation on stroke severity and outcomes: A propensity score matching case-control study","volume":"410","author":"Rodr\u00edguez-Pardo","year":"2020","journal-title":"J Neurol Sci."},{"key":"10.1016\/j.semerg.2023.102136_bib0965","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jamda.2019.08.033","article-title":"VitaminK antagonists and direct oral anticoagulants in nonagenarian patients with atrial fibrillation","volume":"21","author":"Raposeiras-Roub\u00edn","year":"2020","journal-title":"J Am Med Dir Assoc."},{"key":"10.1016\/j.semerg.2023.102136_bib0970","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.recesp.2019.02.003","article-title":"Anticoagulantes orales directos frente a antagonistas de la vitaminaK en pacientes del \u00abmundo real\u00bb con fibrilaci\u00f3n auricular no valvular. Estudio FANTASIIA","volume":"73","author":"Anguita S\u00e1nchez","year":"2020","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib0975","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1080\/03007995.2019.1647735","article-title":"Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: Refase registry","volume":"35","author":"Navarro-Almenzar","year":"2019","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.semerg.2023.102136_bib0980","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/ene.13792","article-title":"The neurologist's approach to cerebral infarct and transient ischaemic attack in patients receiving anticoagulant treatment for non-valvular atrial fibrillation: ANITA-FA study","volume":"26","author":"Zapata-Wainberg","year":"2019","journal-title":"Eur J Neurol."},{"key":"10.1016\/j.semerg.2023.102136_bib0985","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2217\/cer-2018-0134","article-title":"Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: Outcomes from the first observational and prospective study in a Spanish population","volume":"8","author":"Cerd\u00e1","year":"2019","journal-title":"J Comp Eff Res."},{"key":"10.1016\/j.semerg.2023.102136_bib0990","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.aprim.2017.05.009","article-title":"Perfil cl\u00ednico de pacientes con fibrilaci\u00f3n auricular tratados con anticoagulantes orales de acci\u00f3n directa atendidos en atenci\u00f3n primaria. Estudio SILVER-AP","volume":"50","author":"De la Figuera","year":"2018","journal-title":"Aten Primaria."},{"key":"10.1016\/j.semerg.2023.102136_bib0995","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke."},{"key":"10.1016\/j.semerg.2023.102136_bib1000","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/ehjcvp\/pvac063","article-title":"Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial","volume":"9","author":"Talmor-Barkan","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"10.1016\/j.semerg.2023.102136_bib1005","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.3390\/jcm11133788","article-title":"Effectiveness and safety of apixaban in over 3.9 million people with atrial fibrillation: A systematic review and meta-analysis","volume":"11","author":"Buckley","year":"2022","journal-title":"J Clin Med."},{"key":"10.1016\/j.semerg.2023.102136_bib1010","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00228-023-03520-5","article-title":"Non-major bleeding risk of direct oral anticoagulants versus vitaminK antagonists for stroke prevention with atrial fibrillation: A systematic review and network meta-analysis","volume":"79","author":"Ma","year":"2023","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.semerg.2023.102136_bib1015","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1111\/bcp.15464","article-title":"Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies","volume":"88","author":"Archontakis-Barakakis","year":"2022","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.semerg.2023.102136_bib1020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.amjcard.2020.10.064","article-title":"Meta-analysis of safety and efficacy of direct oral anticoagulants versus warfarin according to time in therapeutic range in atrial fibrillation","volume":"140","author":"Lee","year":"2021","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib1025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.recesp.2018.02.023","article-title":"Anticoagulantes orales directos frente a antagonistas de la vitaminaK en pacientes con fibrilaci\u00f3n auricular de la pr\u00e1ctica cl\u00ednica: revisi\u00f3n sistem\u00e1tica y metan\u00e1lisis","volume":"72","author":"Escobar","year":"2019","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib1030","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1007\/s00392-019-01437-7","article-title":"Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: Insights from a large German claims database","volume":"108","author":"Hohnloser","year":"2019","journal-title":"Clin Res Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib1035","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1093\/eurheartj\/ehy411","article-title":"A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation","volume":"39","author":"Cowan","year":"2018","journal-title":"Eur Heart J."},{"key":"10.1016\/j.semerg.2023.102136_bib1040","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1161\/STROKEAHA.118.021990","article-title":"Improved stroke prevention in atrial fibrillation after the introduction of non-vitaminK antagonist oral anticoagulants","volume":"49","author":"Forslund","year":"2018","journal-title":"Stroke."},{"key":"10.1016\/j.semerg.2023.102136_bib1045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ahj.2019.10.017","article-title":"Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people","volume":"220","author":"Maggioni","year":"2020","journal-title":"Am Heart J."},{"key":"10.1016\/j.semerg.2023.102136_bib1050","doi-asserted-by":"crossref","first-page":"e0266658","DOI":"10.1371\/journal.pone.0266658","article-title":"Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain","volume":"17","author":"Escobar Cervantes","year":"2022","journal-title":"PLoS One."},{"key":"10.1016\/j.semerg.2023.102136_bib1055","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.recesp.2014.08.010","article-title":"An\u00e1lisis coste-efectividad de apixab\u00e1n frente a acenocumarol en la prevenci\u00f3n del ictus en pacientes con fibrilaci\u00f3n auricular no valvular en Espa\u00f1a","volume":"68","author":"Bar\u00f3n Esquivias","year":"2015","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib1060","doi-asserted-by":"crossref","first-page":"A375","DOI":"10.1016\/j.jval.2012.08.1015","article-title":"Cost-effectiveness of rivaroxaban versus acenocumarol in the stroke prevention in patients with non-valvular atrial fibrillation in the Spanish setting","volume":"15","author":"Restovic","year":"2012","journal-title":"Value in Health."},{"key":"10.1016\/j.semerg.2023.102136_bib1065","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.recesp.2012.06.006","article-title":"An\u00e1lisis coste-efectividad de dabigatr\u00e1n para la prevenci\u00f3n de ictus y embolia sist\u00e9mica en fibrilaci\u00f3n auricular no valvular en Espa\u00f1a","volume":"65","author":"Gonz\u00e1lez-Juanatey","year":"2012","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.semerg.2023.102136_bib1070","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bmjebm-2020-111634","article-title":"Economic evaluation of direct oral anticoagulants (DOACs) versus vitaminK antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: A systematic review and meta-analysis","volume":"27","author":"Noviyani","year":"2022","journal-title":"BMJ Evid Based Med."},{"key":"10.1016\/j.semerg.2023.102136_bib1075","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.semerg.2018.10.005","article-title":"Perfil de los pacientes con fibrilaci\u00f3n auricular no valvular y riesgo moderado-alto de accidente cerebrovascular que no reciben anticoagulaci\u00f3n oral en Espa\u00f1a","volume":"45","author":"Polo Garc\u00eda","year":"2019","journal-title":"Semergen."},{"key":"10.1016\/j.semerg.2023.102136_bib1080","unstructured":"Sociedad Espa\u00f1ola de Neurolog\u00eda. El atlas del ictus. Espa\u00f1a 2019 [consultado 16 Feb 2021]. Disponible en: https:\/\/www.sen.es\/images\/2020\/atlas\/Atlas_del_Ictus_de_Espana_version_web.pdf"},{"key":"10.1016\/j.semerg.2023.102136_bib1085","unstructured":"Criterios y recomendaciones generales para el uso de los anticoagulantes orales directos (ACOD) en la prevenci\u00f3n del ictus y la embolia sist\u00e9mica en pacientes con fibrilaci\u00f3n auricular no valvular. Informe de Posicionamiento Terap\u00e9utico. UT_ACOD\/V5\/21112016. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ministerio de Sanidad, Servicios Sociales e Igualdad, 21 de noviembre de 2016. Disponible en: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/criterios-anticoagulantes-orales.pdf"},{"key":"10.1016\/j.semerg.2023.102136_bib1090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.semerg.2017.09.005","article-title":"Diferencias en el manejo de los pacientes con fibrilaci\u00f3n auricular seg\u00fan inicie el tratamiento con anticoagulantes orales de acci\u00f3n directa el m\u00e9dico de atenci\u00f3n primaria o el especialista. Estudios SILVER-AP y BRONCE-AP","volume":"44","author":"De la Figuera","year":"2018","journal-title":"Semergen."},{"key":"10.1016\/j.semerg.2023.102136_bib1095","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.semerg.2015.08.004","article-title":"Grado de control y cumplimiento terap\u00e9utico de la anticoagulaci\u00f3n con acenocumarol en atenci\u00f3n primaria","volume":"42","author":"Precioso","year":"2016","journal-title":"Semergen."},{"key":"10.1016\/j.semerg.2023.102136_bib1100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semerg.2013.10.001","article-title":"El m\u00e9dico de familia ante las barreras en la prescripci\u00f3n de los nuevos anticoagulantes orales: heterogeneidad, inequidad y confusi\u00f3n. Posicionamiento de las Sociedades Cient\u00edficas de Atenci\u00f3n Primaria en Espa\u00f1a","volume":"46","author":"Lobos","year":"2014","journal-title":"Semergen."},{"key":"10.1016\/j.semerg.2023.102136_bib1105","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.recesp.2016.03.004","article-title":"On the way to a better use of anticoagulants in nonvalvular atrial fibrillation. Proposed Amendment to the Therapeutic Positioning Report UT\/V4\/23122013","volume":"69","author":"Rold\u00e1n","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"key":"10.1016\/j.semerg.2023.102136_bib1110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.semerg.2018.10.008","article-title":"Anticoagulantes orales directos en la fibrilaci\u00f3n auricular no valvular: c\u00f3mo mejorar su uso en Espa\u00f1a","volume":"45","author":"Anguita","year":"2019","journal-title":"Semergen."}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359323002162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359323002162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:43:22Z","timestamp":1761108202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359323002162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":111,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1138359323002162"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2023.102136","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Situaci\u00f3n actual de los anticoagulantes orales de acci\u00f3n directa en atenci\u00f3n primaria de Espa\u00f1a. Posicionamiento de SEMERGEN en 2023","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2023.102136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102136"}}